Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma

American Journal of Surgical Pathology

Volumn 28, Issue 7, 2004, Pages 914-920

  Wolfsberger, Stefan ^a,b   Fischer, Ingeborg ^b   Höftberger, Romana ^b   Birner, Peter ^a   Slavc, Irene ^a   Dieckmann, Karin ^a   Czech, Thomas ^a   Budka, Herbert ^b   Hainfellner, Johannes ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ependymoma; Ki 67 antigen; Outcome prediction; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; KI 67 ANTIGEN; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY LABELING; ARTICLE; CANCER GRADING; CELL PROLIFERATION; CHILD; DIAGNOSTIC ACCURACY; EPENDYMOMA; FEMALE; HISTOPATHOLOGY; HUMAN; INTRACRANIAL EPENDYMOMA; INTRACRANIAL TUMOR; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PREDICTION; PROGNOSIS; RISK ASSESSMENT; TUMOR CELL; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; EPENDYMOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 3042834730     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200407000-00011     Document Type: Article

References (27)

1. Bennetto L, Foreman N, Harding B, et al. Ki-67 immunolabeling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropathol Appl Neurobiol. 1998;24:434-440.
2. Bouffet E, Foreman N. Chemotherapy for intracranial ependymomas. Childs Nerv Syst. 1999;15:563-570.
3. Cavalla P, Schiffer D. Cell cycle and proliferation markers in neuroepithelial tumors. Anticancer Res. 1997;17:4135-4143.
4. Coons SW, Johnson PC, Pearl DK. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery. 1997;41:878-884.
5. Duffner PK, Krischer JP, Sanford RA, et al. Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg. 1998;28:215-222.
6. Ernestus RI, Schroder R, Stutzer H, et al. Prognostic relevance of localization and grading in intracranial ependymomas of childhood. Childs Nerv Syst. 1996;12:522-526.
7. Figarella-Branger D, Civatte M, Bouvier-Labit C, et al. Prognostic factors in intracranial ependymomas in children. J Neurosurg. 2000;93:605-613.
8. Gerdes J, Becker MH, Key G, et al. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol. 1992;168:85-86.
9. Gerszten PC, Pollack IF, Martinez AJ, et al. Intracranial ependymomas of childhood: lack of correlation of histopathology and clinical outcome, Pathol Res Pract. 1996;192:515-522.
10. Ho DM, Hsu CY, Wong TT, et al. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma. J Neurooncol. 2001;54:77-85.
11. Holden JA, Townsend JJ. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol. 1999;12:1094-1100.
12. Horn B, Heideman R, Geyer R, et al. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol. 1999;21:203-211.
13. Karamitopoulou E, Perentes E, Diamantis I, et al. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB1 monoclonal antibody on archival material. Acta Neuropathol (Berl). 1994;87:47-54.
14. Kleihues P, Cavenee WK. Ependymal tumours. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press, 2000:71-82.
15. Kordek R, Biernat W, Alwasiak J, et al. Proliferating cell nuclear antigen (PCNA) and Ki-67 immunopositivity in human astrocytic tumours. Acta Neurochir (Wien). 1996;138:509-512.
16. Paulino AC, Wen BC, Buatti JM, et al. Intracranial ependymomas: an analysis of prognostic factors and patterns of failure. Am J Clin Oncol. 2002;25:117-122.
17. Perry A. Pathology of low-grade gliomas: an update of emerging concepts. Neurooncol. 2003;5:168-178.
18. Pollack IF, Gerszten PC, Martinez AJ, et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery. 1995;37:655-666.
19. Prayson RA. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry. Ann Diagn Pathol. 1999;3: 11-18.
20. Rezai AR, Woo HH, Lee M, et al. Disseminated ependymomas of the central nervous system. J Neurosurg. 1996;85:618-624.
21. Ritter AM, Hess KR, McLendon RE, et al. Ependymomas: MIB-1 proliferation index and survival. J Neurooncol. 1998;40:51-57.
22. Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg. 1998;88: 695-703.
23. Rushing EJ, Brown DF, Hladik CL, et al. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype. Mod Pathol. 1998;11:464-470.
24. Schröder R, Ploner C, Ernestus RI. The growth potential of ependymomas with varying grades of malignancy measured by the Ki-67 labelling index and mitotic index. Neurosurg Rev. 1993;16:145-150.
25. Suzuki S, Oka H, Kawano N, et al. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas. Brain Tumor Pathol. 2001;18:151-154.
26. Taniguchi K, Wakabayashi T, Yoshida T, et al. Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas. J Neurosurg. 1999;91:477-482.
27. Verstegen MJ, Leenstra DT, Ijlst-Keizers H, et al. Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis. J Neurooncol. 2002;56:21-28.